BioCentury | Dec 9, 2020
Emerging Company Profile

Tallac: linking antibodies to DNA-triggered innate immunity

Tallac debuted last week with a $62 million series A round to advance a pipeline of systemically delivered antibody conjugates designed to trigger innate immunity against cancer.  The tranched round...
BioCentury | Dec 5, 2020

Seer posts triple-digit gain as trio of new listings adds to 2020’s record NASDAQ haul

...half of the $241.5 million it wound up with.Lead product candidate SBT6050, which links a TLR8 agonist...
BioCentury | Nov 25, 2020
Management Tracks

DBV CSO stepping down; plus moves at Idera, Ultimovacs, Omniome, Humacyte and Aelis Farma

...and chairman of DBV’s scientific advisory board. Daniel Soland will join cancer and rare disease company Idera...
...Inc. (NASDAQ:IDRA) on Jan. 4, 2021 as SVP and COO. He was CEO of uniQure N.V. (NASDAQ:QURE). Idera...
...for research and development at H. Lundbeck A/S (CSE:LUN) before retiring in 2018. Danielle Golovin DBV Technologies S.A. Idera...
BioCentury | Oct 28, 2020

Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

Apellis, Sobi enter territorial deal for C3 inhibitorApellis Pharmaceuticals Inc. (NASDAQ:APLS) granted Swedish Orphan Biovitrum AB (SSE:SOBI) exclusive ex-U.S. rights to systemic therapy pegcetacoplan (APL-2), an inhibitor of C3. The partners will jointly develop the...
BioCentury | Sep 24, 2020

Sept. 23 Quick Takes: Zai raises $776M, Silverback $85M; plus Novartis, PureTech, UCB and more

...existing investors. The company’s lead candidate SBT6050, a conjugate comprising a HER2-targeting mAb linked to a TLR8 agonist...
BioCentury | Aug 8, 2020

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

NASDAQ debuts by Syncona gene therapy company Freeline and Checkmate, a cancer company co-founded by Art Krieg, pushed the year’s IPO haul to $14.7 billion, more than double the amount raised over the same period...
BioCentury | Aug 4, 2020

Dynavax deal gives drug delivery play TriSalus its first therapeutic candidate

Monday’s deal with Dynavax marks TriSalus’ pivot into therapeutics development. TriSalus Life Sciences gained exclusive, worldwide rights to SD-101, a TLR9 agonist, from Dynavax Technologies Corp. (NASDAQ:DVAX). TriSalus will pay Dynavax $5 million up front...
BioCentury | Aug 4, 2020

Interest in protein degradation runs hot as Kymera files for IPO

Atlas-backed Kymera has at least one comparator among preclinical protein degradation companies as it seeks a NASDAQ listing -- and it could soon be followed by another company in the same category. A regulatory filing...
BioCentury | Jul 21, 2020

As trio of companies enter IPO queue, four more propose terms

Cross-border licensing company Everest, gene therapy play Freeline and oncology company Checkmate are the latest companies to enter the IPO queue, joining a long list of companies aspiring to go public in a season when...
BioCentury | Jul 2, 2020
Emerging Company Profile

Bolt’s myeloid twist on ADCs charged up with $93.5M series C

...cells, prompting phagocytosis of both the compound and the tumor cell it’s bound to. The TLR7/TLR8 agonist...
Items per page:
1 - 10 of 682